Vertigo due to cerebral arteriosclerosis (blood stasis syndrome)
Conditions
Interventions
Experimental group versus control group:During the experiment, it is forbidden to add any Chinese and western medicine with the same efficacy as the experimental medicine and any medicine that affects
Sponsors
Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
40 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients with mild cerebral arteriosclerosis and symptoms of vertigo; 2. Meet the TCM syndrome differentiation standards of blood stasis; 3. Aged 40 ~ 70 years old male and female; 4. Those who have no recent family planning (negative urine pregnancy test within 72 hours before the start of the trial for women of child-bearing age) and agree to take effective non-drug contraceptive measures during the study period; 5. Agree to participate in the clinical trial and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. dizziness caused by other reasons, including the vascular vestibular central vertigo, BPP (BPV), vestibular neuronitis, labyrinthitis, meini disease (MD), intracranial tumors caused by dizziness, vestibular migraine vertigo, low blood pressure or hypertension caused by dizziness, low blood sugar, mental obstacle dizziness, vertigo motion sickness or drugs etc.; 2. concomitant heart failure, advanced tumor, blood, central nervous system (if there is a history of epilepsy) or other serious or progressive diseases of the system; 3. Patients with severe hepatorenal disease or abnormal hepatorenal function examination (ALT, AST 1.5 times of normal upper limit, Cr > normal upper limit); 4. Patients with unsatisfactory hypertension control and > 140/90 mmHg blood pressure after systemic hypotension treatment; 5. Patients with other diseases requiring similar drug treatment as the experimental drug; 6, combined with neurological, mental disorders and unable to cooperate; 7. Suspect or have a history of alcohol or drug abuse; 8. Pregnant or lactating women or those with recent family planning; 9. Participated in other clinical trials within the first 3 months; 10. Allergic constitution, allergic to the test drug or its components.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of the TCM symdrom; | — |
Countries
China
Contacts
Public ContactYue Changlin
Zhejiangjiuxu Pharmaceutical.Co.,Ltd
Outcome results
None listed